CN116462669A - SOS1 and EGFR double-target compound, and preparation method and application thereof - Google Patents
SOS1 and EGFR double-target compound, and preparation method and application thereof Download PDFInfo
- Publication number
- CN116462669A CN116462669A CN202310733464.2A CN202310733464A CN116462669A CN 116462669 A CN116462669 A CN 116462669A CN 202310733464 A CN202310733464 A CN 202310733464A CN 116462669 A CN116462669 A CN 116462669A
- Authority
- CN
- China
- Prior art keywords
- compound
- sos1
- cancer
- pharmaceutically acceptable
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 title claims abstract 6
- 102000057028 SOS1 Human genes 0.000 title claims abstract 6
- 108700022176 SOS1 Proteins 0.000 title claims abstract 6
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 title claims abstract 6
- 101150100839 Sos1 gene Proteins 0.000 title claims abstract 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title claims abstract 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title claims abstract 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- 102000016914 ras Proteins Human genes 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 2
- 201000008017 ovarian lymphoma Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000006907 apoptotic process Effects 0.000 abstract description 9
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000005917 in vivo anti-tumor Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 230000005918 in vitro anti-tumor Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 5
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 229960002584 gefitinib Drugs 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- ASNVMKIDRJZXQZ-ZCFIWIBFSA-N (1r)-1-(3-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=CC(F)=C1 ASNVMKIDRJZXQZ-ZCFIWIBFSA-N 0.000 description 1
- VWBHHSJRPOSFGG-UHFFFAOYSA-N (4-chloro-7-methoxyquinazolin-6-yl) acetate Chemical compound C1=NC(Cl)=C2C=C(OC(C)=O)C(OC)=CC2=N1 VWBHHSJRPOSFGG-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000686246 Homo sapiens Ras-related protein R-Ras Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102100024683 Ras-related protein R-Ras Human genes 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- -1 glidants Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 102200006538 rs121913530 Human genes 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an SOS1 and EGFR double-target compound and a preparation method and application thereof, and also discloses a pharmaceutical composition, wherein the preparation is prepared from the double-target compound or a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or auxiliary materials, and the compound has SOS1 and EGFR double-inhibition activity, can inhibit proliferation of tumor cells, promote apoptosis of tumor cells, shows excellent in-vivo and in-vitro anti-tumor activity and has better drug-forming prospect.
Description
Technical Field
The invention relates to an SOS1 and EGFR double-target compound, in particular to an SOS1 and EGFR double-target compound, a preparation method and application thereof.
Background
Epidermal Growth Factor (EGF) receptor (EGFR) is a transmembrane protein with tyrosine kinase activity, and binding of growth factor to EGFR activates EGFR, which in turn activates its mediated downstream RAS/AKT pathway, which inhibits apoptosis and promotes proliferation, invasion, metastasis and angiogenesis. In addition, EGFR can mediate progression of the cell cycle by promoting passage of cells through the G1 phase by activating the cyclin dependent kinase 4/6 (CDK 4/6) -cyclin D (cyclin D) complex. EGFR is therefore an important target for prostate cancer intervention. However, numerous studies have shown that overexpression of EGFR is associated with a poor prognosis for prostate cancer. Currently, EGFR-targeting drugs such as gefitinib are already marketed in batches. Gefitinib has been reported to have limited single drug activity against androgen refractory prostate cancer, and its combination with other drugs can improve the therapeutic effect.
SOS1 (son of seveless 1) is a key nucleotide exchange factor for KRAS, converting GDP-bound KRAS (inactive) to GTP-bound KRAS (active form); SOS1 has been identified as the junction of RAS-related signal pathways that play an important role in the development of prostate carcinogenesis. SOS1 is therefore also a key target for prostate cancer treatment. However, only one SOS1 small molecule inhibiting BI 1701963 has entered the clinical study stage so far, and both clinical trials of this small molecule inhibitor (NCT 04835714, NCT 04627142) have been declared to be terminated due to severe toxicity. To date, there are no available inhibitors for SOS1 on the market.
Combination therapy has been widely used for the treatment of complex diseases caused by abnormalities in various signaling pathways, often with better anti-tumor efficacy than single-target combination therapy. However, co-administration often suffers from the following problems: 1) Acute toxicity and delayed toxicity may be more likely to occur when administered in combination, particularly when less selective agents are used in combination; 2) Because the combined administration relates to a plurality of medicines, the proportion and the dosage of the medicines need to be considered, the administration mode is complex, and the compliance of patients is easy to be poor; 3) The combined administration can cause mutual interference of medicines in-vivo metabolism, and the pharmacokinetic properties of the medicines cannot be accurately predicted; 4) Adverse reactions caused by drug-drug interactions may occur in combination, and the pharmacodynamic characteristics of combination are difficult to predict accurately.
Disclosure of Invention
The invention aims to: the invention aims to provide SOS1 and EGFR double-target compounds with good curative effect and reduced drug resistance and toxicity, and a second aim of the invention is to provide a preparation method and application of the double-target compounds.
The technical scheme is as follows: the invention discloses an SOS1 and EGFR double-target compound or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the compound has a structural formula shown in a formula (I):
。
the preparation method of the compound comprises the following steps:
(1) Adding the raw materials 1 and 2 into isopropanol, stirring and heating, vacuum concentrating, separating and purifying to obtain an intermediate 3;
(2) Dissolving the intermediate 3, the compound 4 and triphenylphosphine into dichloromethane, cooling, stirring and reacting, then dropwise adding diisopropyl azodicarboxylate, stirring and reacting at room temperature, concentrating in vacuum, separating and purifying to obtain a SOS1 and EGFR double-target compound;
。
the invention also provides a pharmaceutical composition, which is a preparation prepared from a double-target compound shown in the formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers and/or auxiliary materials.
Preferably, the pharmaceutically acceptable carrier and/or adjuvant comprises diluents, binders, surfactants, wetting agents, lubricants, fillers, disintegrants, colorants, glidants, stabilizers, suspending agents, buffers, emulsifiers, granulating agents, anti-adherents, gelling agents, absorption retarders, dissolution inhibitors, enhancers, adsorbents, chelating agents, preservatives, colorants, flavoring agents, or sweeteners.
Preferably, the preparation is tablet, capsule, oral liquid, injection, lyophilized powder for injection, transdermal agent, aerosol, solid preparation, liposome, sustained and controlled release preparation, pill, suppository, granule, powder, nanometer preparation, syrup, medicated wine, tincture or distillate.
The compound or the stereoisomer or the pharmaceutically acceptable salt thereof, and the application of the pharmaceutical composition in preparing SOS1/EGFR double-target inhibitor drugs.
The use of the above compound or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the above pharmaceutical composition for the manufacture of a medicament for inhibiting the RAS signaling pathway.
The application of the compound or the stereoisomer or the pharmaceutically acceptable salt thereof in preparing medicaments for treating and/or preventing tumors.
Further, the tumor includes prostate cancer, colon cancer, lung cancer, breast cancer, stomach cancer, esophageal cancer, cervical cancer, glioma, nasopharyngeal carcinoma, liver cancer, ovarian cancer or lymphoma.
The beneficial effects are that: compared with the prior art, the invention has the following remarkable advantages: (1) SOS1 and EGFR double-target compounds can effectively inhibit cell proliferation and promote apoptosis, and have good in-vivo anti-tumor activity and no obvious toxic or side effect; (2) The double targets of SOS1 and EGFR can generate cytotoxicity on EGFR inhibitor drug-resistant cancer cells, and simultaneously reduce toxicity to normal tissues caused by widely inhibiting RAS channels, so that a synergistic anti-tumor effect is achieved.
Drawings
FIG. 1 is a diagram of SE-9 in example 1 1 H NMR spectrum;
FIG. 2 is a MS spectrum of SE-9 in example 1;
FIG. 3 is an HPLC chromatogram of SE-9 in example 1;
FIG. 4 shows the result of SE-9 inhibiting SOS1 in example 4;
FIG. 5 is a graph showing the results of SE-9 inhibition of EGFR in example 5;
FIG. 6 shows the results of SE-9 promoting apoptosis of PC-3 cells in example 6;
FIG. 7 shows the results of SE-9 inhibiting PC-3 cell proliferation in example 7;
FIG. 8 shows the results of SE-9 inhibiting PC-3 cell proliferation in example 7;
FIG. 9 is the effect of SE-9 on tumor growth in nude mice in example 8;
FIG. 10 shows the effect of SE-9 on the body weight and blood biochemical index of nude mice in example 8, showing the toxic side effects of SE-9 on nude mice.
Description of the embodiments
The technical scheme of the invention is further described below with reference to the accompanying drawings.
Example 1
Preparation of SOS1 and EGFR double-target compound SE-9
(1) 4-chloro-7-methoxyquinazolin-6-yl acetate (267 mg, 1 mmol) and(R)1- (3-fluorophenyl) ethylamine (418 mg, 3 mmol) was dissolved in isopropanol and the reaction mixture was stirred at 60℃for 8h, then concentrated in vacuo and the crude product purified on a silica gel column to give intermediate 3 (33%). 1 H NMR (400 MHz, DMSO)δ9.42 (s, 1H), 8.23 (s, 1H), 7.98 (d,J= 7.9 Hz, 1H), 7.71 (s, 1H), 7.37 – 7.31 (m,1H), 7.27 – 7.22 (m, 2H), 7.09 (s, 1H), 7.04 – 6.99 (m, 1H), 5.57 – 5.50 (m, 1H), 3.93 (s, 3H), 1.55 (d,J= 7.1 Hz, 3H)。
(2) Intermediate 3 (157 mg, 0.5 mmol) obtained in step (1), tetrahydro-2H-pyran-4-ol (61 mg,0.6 mmol) and triphenylphosphine (183 mg,0.6 mmol) were dissolved in dichloromethane; stirring the reaction mixture at 0 ℃ for reaction for 10 min; after that, diisopropyl azodicarboxylate (121 mg,0.6 mmol) was added dropwise to the mixture. Mixing the reactionStirring at room temperature for reaction 6h, and concentrating in vacuum; the crude product was purified on a silica gel column to give compound SE-9 (21%). 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.27 (s, 1H), 8.06 (d,J= 7.7 Hz, 1H), 7.87 (s, 1H), 7.67 – 7.51 (m, 1H), 7.42 – 7.30 (m, 1H), 7.29 – 7.18 (m, 2H), 7.12 (s, 1H), 7.09 – 6.97 (m, 1H), 5.59 (p,J= 7.6, 7.2 Hz, 1H), 4.72 (dt,J= 8.1, 4.1 Hz, 1H), 3.90 (s, 4H), 3.52 (t,J= 9.2 Hz, 2H), 2.03 (s, 1H), 2.00 (s, 1H), 1.67 (ddd,J= 12.7, 8.5, 3.9 Hz, 2H), 1.59 (d,J=7.0 Hz, 3H) (as in fig. 1); MS (ESI) M/z 398.2 [ M+H] + (as in figure 2); HPLC 99.024% (R) t = 10.080 min) (mobile phase a: meOH, B: H 2 O, ratio 70:30, column temperature: 40. DEG C, flow rate: 1mL/min, detector: 254 nm) (see fig. 3).
Example 2
Inhibition of SOS1 and EGFR by SE-9: SOS1 Single target inhibitor AXE and SE-9 Compounds were first dissolved in buffer (10 mM HEPES (pH 7.4), 5mM MgCl 2 150 mM NaCl, 1mM DTT, 0.0025% Igepal, 0.05% BSA) followed by SOS1 (40 nM, 2.5. Mu.L) and incubation at 25℃for 30 min. Then 2.5. Mu.L of buffer (80 nM KRAS) was added G12C 1 ng/. Mu.L of Mab Anti-6 His-XL665, 1 ng/. Mu.L of Mab Anti-GSH-Eu cryptat) and incubating the mixture at 25℃for 60 minutes. Homogeneous Time Resolved Fluorescence (HTRF) signals were recorded at an excitation wavelength of 320 nm to determine the inhibition of SOS1 by the compound. In addition, different concentrations of the EGFR single-target inhibitor gefitinib, SE-9 compound and EGFR kinase were added to the assay plate, followed by addition of the ATP-substrate mixture to initiate the enzymatic reaction. After 1 hour of reaction at room temperature, EDTA buffer was added to stop the reaction. Finally, the inhibition of EGFR by the compounds was determined by adding the detection solution to the assay plate and incubating 1 h. The results are shown in Table 1, SE-9 has obvious double inhibition effect on SOS1 and EGFR, and the inhibition effect is superior to that of SOS1 single-target inhibitor AXE and EGFR single-target inhibitor gefitinib.
Example 3
In vitro inhibition of tumor cells by SE-9: respectively administering different concentrations of TN-2 compound to human prostate cancer PC-3 cells, human colorectal adenocarcinoma DLD-1 cells, human liver cancer HepG2 cells, human chronic myelogenous leukemia K-562 cells and human lung cancer A549 cells, and placing at 37deg.C and 5% CO 2 For 72h, and determining the inhibition rate of the compound on tumor cells by using a tetramethyl azoazole (MTT) colorimetric method. As shown in Table 2, SE-9 has significant in vitro inhibitory activity against PC-3, DLD-1, hepG2, K-562 and A549 cells.
Example 4
Inhibition of cellular SOS1 Activity by SE-9: RAS-GTP levels were determined in PC-3 cells treated with different concentrations of SE-9 (0, 0.5, 12.5. Mu.M) and EGF was used as a positive control for SOS1 activation. As shown in FIG. 4, SE-9 was able to significantly reduce RAS-GTP levels in cells, whereas the positive control group had elevated RAS-GTP levels.
To further confirm the inhibition of SOS1 by SE-9, the levels of the RAS downstream effectors p-ERK and p-AKT were measured under the same conditions. As shown in FIG. 4, the changes in p-AKT and p-ERK levels were consistent with the changes in RAS-GTP, i.e., the decrease in p-AKT and p-ERK levels in SE-9 treated cells, and the positive control group had elevated p-AKT and p-ERK levels (A in FIG. 4 and B in FIG. 4). The results show that compound SE-9 mediated SOS1 inhibition can inhibit RAS signaling and result in a decrease in downstream effectors p-AKT and p-ERK.
Example 5
Inhibition of cellular EGFR activity by SE-9: PC-3 cells were treated with different concentrations of SE-9 (0, 0.5, 12.5. Mu.M) and Western blot analysis was performed. The results indicate that EGF, a positive activator for EGFR, significantly induces p-EGFR levels, whereas SE-9 treatment significantly attenuated this effect. Furthermore, SE-9 treatment significantly blocked EGF-mediated up-regulation of p-AKT levels compared to EGF alone treatment group, and the results in FIG. 5 indicate that SE-9 is a highly active EGFR inhibitor.
Example 6
Effect of SE-9 on apoptosis of PC-3 cell line: cells were treated with gradient concentration of SE-9 (0,0.5,2.5,12.5. Mu.M) and prepared in DMSO as a solvent, and after treatment, cells were double labeled with Annexin V-FITC and PI. A in FIG. 6 shows that SE-9 treatment can promote apoptosis of PC-3 cells. Further, as shown in B in FIG. 6 and C in FIG. 6, the apoptosis-detecting proteins suggest that SE-9 treatment can induce increased expression of the apoptosis proteins clear PARP and clear caspase 3, and the results indicate that SE-9 can promote apoptosis of PC-3 cells.
Example 7
The influence of SE-9 on the PC-3 cell colony forming ability is examined through a cell cloning experiment, and the independent viability of cells is expressed by the cell colony forming rate and the colony forming size, and the specific process is as follows: laying 500-800 cells/hole in 6-hole plate, culturing in 37 deg.C constant temperature incubator to adhere. After 48h, 2mL of fresh complete medium was changed, and different concentrations of SE-9 (0, 0.5,2.5, 12.5. Mu.M) were added, and the culture was continued in an incubator with DMSO as the solvent. The medium was then changed every 3 days. After 2 weeks, the supernatant was discarded, and after washing with PBS, pre-chilled methanol was added for 30 minutes. Then, PBS was added for washing, and 0.1% crystal violet staining solution was added for staining for 30 minutes. Finally, PBS is washed to the bottom of the pore plate to be transparent and colorless. Standing for several days, naturally drying, and photographing. As shown in FIG. 7, SE-9 can inhibit the clonogenic capacity and cell viability of PC-3 cell lines and is concentration dependent.
Cell proliferation potency was tested using EdU: cells were plated in 96-well plates at 1 w/well and placed in a 37℃incubator overnight to allow adherence. The next day 200. Mu.l of complete medium containing different concentrations of SE-9 (0, 0.5,2.5, 12.5. Mu.M) was changed, and the culture was continued in an incubator with DMSO as the solvent. After 24h of drug action, complete medium containing EdU reagent (10. Mu.M) was added and incubated at 37℃for 2h. PBS is added for 5min, 4% paraformaldehyde is added for 30min at room temperature for neutralization with 2mg/mL glycine for 5min, PBS is added for 5min, 0.5% Triton X-100 is added for permeation for 20min, and PBS is added for 5min. The reaction solution was incubated with kFluor488-azide at room temperature for 30min and washed with PBS for 5min. Incubation with 1 Xhoechst 33342 reaction solution at room temperature for 30min in dark place, PBS cleaning, and imaging under a fluorescence microscope, as shown in FIG. 8, edU proliferation test results also indicate that SE-9 treatment can inhibit cell proliferation activity, and that SE-9 can inhibit PC-3 cell proliferation.
Example 8
Effect of SE-9 on tumor growth in PC-3 cell ectopic engrafted tumor nude mice: adapting 6-8 week old BALB/C female nude mice to environment for about 1 week, digesting PC-3 cells with pancreatin, centrifuging at 1300rpm for 4min, adding 5mL fresh FBS-free DMEM, washing, counting, and adjusting concentration to 1×10 8 Each cell/ml was inoculated subcutaneously into mice at 100. Mu.L each. The tumor waiting volume is as long as 100mm 3 Administration was then started. Each cell was randomly divided into 3 groups of 6, each of which was SE-9 (5 mg/kg,20 mg/kg) dosing group, solvent blank. Intraperitoneal administration was performed on a group-by-group basis, 1 time every 4 days, and each mouse was given 100. Mu.L of drug (SE-9 in 4% DMSO+1% Tween-80+95% sterile PBS) or solvent blank (4% DMSO+1% Tween-80+95% sterile PBS) for 24 consecutive days. The body weight and tumor volume of the nude mice were recorded every 4 days during the experiment, and the growth of the nude mice was observed. Tumor tissue was taken at the end of the experiment, tumor weight was measured and inhibition ratio was calculated, inhibition ratio= (control tumor volume-dosing tumor volume/control tumor volume) ×100%. As shown by a in fig. 9 to E in fig. 9, the tumor volume of the SE-9-dosed group was dose-dependently reduced compared to the control group. In addition, the tumor weight was significantly lower in the SE-9-dosed group than in the control group (F in FIG. 9). Further, the measurement of G in FIG. 9 by TUNEL, CD31 and Ki67 reveals that SE-9 is capable of inducing apoptosis and inhibiting angiogenesis in vivo. Finally, fig. 10 shows that the body weight and blood biochemical indexes of the nude mice are detected, and the obtained results show that SE-9 has no obvious influence on the body weight of the nude mice and the biochemical indexes such as alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), hematuria (BUN), creatinine (CRE) and the like. These results indicate that SE-9 has good in vivo anti-tumor activity and no obvious toxic or side effects.
Claims (7)
1. A SOS1 and EGFR dual-target compound, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, wherein the compound has the structural formula shown in formula (I):
。
2. a process for the preparation of a compound as claimed in claim 1, comprising the steps of:
(1) Adding the raw materials 1 and 2 into isopropanol, stirring and heating, vacuum concentrating, separating and purifying to obtain an intermediate 3;
(2) Dissolving the intermediate 3, the compound 4 and triphenylphosphine into dichloromethane, cooling, stirring and reacting, then dropwise adding diisopropyl azodicarboxylate, stirring and reacting at room temperature, concentrating in vacuum, separating and purifying to obtain a SOS1 and EGFR double-target compound;
。
3. a pharmaceutical composition characterized by: the pharmaceutical composition is a preparation prepared from the double-target compound or the stereoisomer or the pharmaceutically acceptable salt thereof in claim 1 and one or more pharmaceutically acceptable carriers and/or auxiliary materials.
4. Use of a compound according to claim 1 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 3 for the preparation of a SOS1/EGFR dual-target inhibitor drug.
5. Use of a compound according to claim 1 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 3 in the manufacture of a medicament for inhibiting the RAS signaling pathway.
6. Use of a compound according to claim 1 or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 3 for the manufacture of a medicament for the treatment and/or prophylaxis of tumors.
7. The use according to claim 6, wherein the tumour comprises prostate cancer, colon cancer, lung cancer, breast cancer, gastric cancer, oesophageal cancer, cervical cancer, glioma, nasopharyngeal carcinoma, liver cancer, ovarian cancer or lymphoma.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310733464.2A CN116462669B (en) | 2023-06-20 | 2023-06-20 | SOS1 and EGFR double-target compound, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310733464.2A CN116462669B (en) | 2023-06-20 | 2023-06-20 | SOS1 and EGFR double-target compound, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116462669A true CN116462669A (en) | 2023-07-21 |
CN116462669B CN116462669B (en) | 2023-09-22 |
Family
ID=87181106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310733464.2A Active CN116462669B (en) | 2023-06-20 | 2023-06-20 | SOS1 and EGFR double-target compound, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116462669B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000644A1 (en) * | 2000-06-24 | 2002-01-03 | Astrazeneca Ab | Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases |
US20050070560A1 (en) * | 2003-09-30 | 2005-03-31 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
WO2022262691A1 (en) * | 2021-06-17 | 2022-12-22 | Beijing Innocare Pharma Tech Co., Ltd. | Heterocyclic compounds as sos1 inhibitors |
-
2023
- 2023-06-20 CN CN202310733464.2A patent/CN116462669B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000644A1 (en) * | 2000-06-24 | 2002-01-03 | Astrazeneca Ab | Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases |
US7001904B1 (en) * | 2000-06-24 | 2006-02-21 | Astrazeneca Ab | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases |
US20050070560A1 (en) * | 2003-09-30 | 2005-03-31 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation |
WO2022262691A1 (en) * | 2021-06-17 | 2022-12-22 | Beijing Innocare Pharma Tech Co., Ltd. | Heterocyclic compounds as sos1 inhibitors |
Non-Patent Citations (1)
Title |
---|
杨宁等: "KRAS 小分子抑制剂的研究与应用进展", 临床药物治疗杂志, vol. 20, no. 3, pages 13 - 21 * |
Also Published As
Publication number | Publication date |
---|---|
CN116462669B (en) | 2023-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116462669B (en) | SOS1 and EGFR double-target compound, and preparation method and application thereof | |
KR20200135945A (en) | Hepatocellular carcinoma treatment | |
CN107151233A (en) | Pyridine derivatives containing hydrazone and application thereof | |
CN116444447B (en) | SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof | |
WO2002041828A2 (en) | Houttuyninum compositions and methods for inhibiting the activity of erbb-2 based thereon | |
EP3984543A1 (en) | Use of extract from rabbit skin inflamed by vaccinia virus in treatment of cancer | |
WO2013107225A1 (en) | N-((4-chloro-3-trifluoromethyl)phenyl)-n'-(2-fluoro-4-((2-hydroxymethylaminoformyl)-4-pyridyloxo)phenyl)urea and use thereof as anti-cancer drug | |
CN113444074B (en) | Compound with EGFR (epidermal growth factor receptor) and Wnt dual inhibition effects as well as preparation method and application thereof | |
CN110840868B (en) | Application of bromhexine in preparation of anti-cancer drugs | |
CN113754593B (en) | BRD4 protein inhibitor and application thereof | |
CN108619145B (en) | Application of compound in treating tumor | |
CN108456184B (en) | Small molecule inhibitor combined with targeting EGFR and EPS8 and application thereof | |
CN112957357A (en) | Target KLF4 ubiquitination small molecule inhibitor and application thereof | |
CN102688490B (en) | Pharmaceutical composition containing evodiamine, evodiamine derivative and Bc1-2 inhibitor, and the application | |
CN106995368B (en) | non-ATP competitive FGFR1 inhibitor and application thereof | |
KR20200023231A (en) | Novel use of pyrimidine derivatives containing LRRK kinase inhibitors as active ingredients | |
CN118161509B (en) | Application of MAPK12 inhibitor and derivatives thereof in preparation of antitumor drugs | |
CN115414363B (en) | Anti-liver cancer composition and application of phenformin in preparation of anti-liver cancer drug sensitizer | |
CN116531389B (en) | Application of VS6766 combined with tripterine and pharmaceutical composition | |
WO2019056375A1 (en) | Acid-sensitive gefitinib axially substituted silicon phthalocyanine complex and preparation method therefor and medical use thereof | |
WO2019056376A1 (en) | Acid-sensitive gefitinib-fluoroboronbipyrrole derivative and preparation method therefor and medical use thereof | |
CN115286574B (en) | BLVRB enzyme function inhibitor and preparation method and application thereof | |
CN109942562B (en) | Five-membered heterocyclic diazine compound containing aryl structure and preparation method and application thereof | |
RU2777535C2 (en) | Therapeutic agent for treatment of hepatocellular carcinoma | |
CN107737123B (en) | Cancer treatment medicine capable of killing tumor stem cells and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |